Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
12.24
+0.74 (6.43%)
Mar 4, 2026, 2:02 PM EST - Market open
Tango Therapeutics Employees
Tango Therapeutics had 155 employees as of December 31, 2024. The number of employees increased by 15 or 10.71% compared to the previous year.
Employees
155
Change (1Y)
15
Growth (1Y)
10.71%
Revenue / Employee
$429,039
Profits / Employee
-$648,484
Market Cap
1.65B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 155 | 15 | 10.71% |
| Dec 31, 2023 | 140 | 30 | 27.27% |
| Dec 31, 2022 | 110 | 19 | 20.88% |
| Sep 30, 2022 | 109 | 26 | 31.33% |
| Jun 30, 2022 | 103 | 17 | 19.77% |
| Mar 31, 2022 | 98 | 21 | 27.27% |
| Dec 31, 2021 | 91 | 14 | 18.18% |
| Sep 30, 2021 | 83 | 6 | 7.79% |
| Jun 30, 2021 | 86 | - | - |
| Mar 31, 2021 | 77 | - | - |
| Dec 31, 2020 | 77 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Vir Biotechnology | 367 |
| Biohaven | 256 |
| EyePoint | 165 |
| Capricor Therapeutics | 160 |
| AnaptysBio | 136 |
| Nanobiotix | 103 |
| Savara | 59 |
TNGX News
- 6 weeks ago - Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - GlobeNewsWire
- 2 months ago - Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewsWire
- 2 months ago - Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy - Seeking Alpha
- 4 months ago - Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript - Seeking Alpha
- 4 months ago - Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement - Benzinga